Sol-Gel Technologies Ltd. (SLGL)
1.23
0.00 (0.00%)
At close: Jan 14, 2025, 3:59 PM
undefined% (undefined)
| Bid | 1.16 |
| Market Cap | 34.26M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.34 |
| PE Ratio (ttm) | -3.62 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 1.25 |
| Volume | 400,148 |
| Avg. Volume (20D) | 510,127 |
| Open | 1.23 |
| Previous Close | 1.23 |
| Day's Range | 1.22 - 1.40 |
| 52-Week Range | 0.33 - 1.65 |
| Beta | undefined |
About SLGL
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream ...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 1, 2018
Employees 36
Stock Exchange NASDAQ
Ticker Symbol SLGL
Website https://www.sol-gel.com
Analyst Forecast
According to 2 analyst ratings, the average rating for SLGL stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 306.50% from the latest price.
Buy 50.00%
Hold 50.00%
Sell 0.00%
Next Earnings Release
Sol-Gel Technologies Ltd. is scheduled to release its earnings on Mar 12, 2025,
before market opens.
Analysts project revenue of $1.82M, reflecting a 307.16% YoY growth and earnings per share of -0.15, making a -11.76% decrease YoY.
Analysts project revenue of $1.82M, reflecting a 307.16% YoY growth and earnings per share of -0.15, making a -11.76% decrease YoY.
2 months ago ·
Source
+3%
Sol-Gel Technologies shares are trading higher aft...
Unlock content with
Pro Subscription
